Julkaistu 21.9.2020

Tervetuloa syksyn ensimmäiseen syöpäseminaariin torstaina 24.9. klo 14–15!

Seminaari järjestetään etäyhteydellä, esityskieli on englanti. Seminaarin järjestää Tays syöpäkeskus yhteistyössä Lääketieteen ja terveysteknologian tiedekunnan kanssa

Etäyhteyden linkki

Zoom-kokouksen linkki:
https://harvard.zoom.us/j/95597409653?pwd=ajdUcXRVcllkaW5mY3daS01IY2svUT09

Salasana: 113073

Ohjelma

Dr. Heidi Haikala:
Developing next-generation targeted therapies for drug resistant non-small cell lung cancers
Dana-Farber Cancer Institute & Harvard Medical School, USA.

Host: Annika Auranen

Lisätietoja puhujasta:

Heidi Haikala received her PhD in Translational Cancer Biology Research Program, University of Helsinki under the supervision of Dr. Juha Klefström. She is currently working as a Research Fellow in the laboratory of Dr. Pasi Jänne in Dana-Farber Cancer Institute & Harvard Medical School. 

The Jänne Lab’s research integrates bench-based studies with translational research and clinical trials of novel therapeutic agents in lung cancer. The lab’s main interest centers on understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. 

Heidi is currently developing new targeted therapy strategies to prevent and reverse EGFR inhibitor resistance in lung cancer. This includes therapeutic strategies to directly degrade the EGFR receptor by using the ubiquitin-proteasome pathway, as well as studying new ways to vertically or in parallel block the EGFR survival signaling by using combination strategies.  The research utilizes innovative patient tumor-derived ex vivo culture systems, including organoids, microfluidic chip cultures, and co-culture systems.

Lisätietoja: www.jannelab.org